BAYRY News
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
Zacks
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
Zacks
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
Zacks
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
Zacks
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
Zacks
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.
Zacks
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Zacks
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
Zacks
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Zacks
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
Zacks